linifanib linifanib linifanib (abt-869) is a structurally novel, potent inhibitor of receptor tyrosine kinases (rtk), vascular endothelial growth factor (vegf) and platelet-derived growth factor (pdgf) with ic50 of 0.2, 2, 4, and 7 nm for human endothelial cells, pdgf receptor beta (pdgfr-β), kdr, and colony stimulating factor 1 receptor (csf-1r), respectively. it has much less activity (ic50s > 1 μm) against unrelated rtks, soluble tyrosine kinases, or serine/threonine kinases. in vivo linifanib is effective orally in mechanism-based murine models of vegf-induced uterine edema (ed50 = 0.5 mg/kg) and corneal angiogenesis (>50%inhibition, 15 mg/kg). linifanibclinical dataatc codenonelegal statuslegal status investigational identifiers iupac name 1--3-(2-fluoro-5-methylphenyl)urea cas number796967-16-3pubchem cid11485656iuphar/bps5657chemspider9660475 yuniico93x137cwkeggd09635 ychebichebi:91435chemblchembl223360 ycomptox dashboard (epa)dtxsid40229834 echa infocard100.206.772 chemical and physical dataformulac17h15fn5omolar mass324.339 g·mol−13d model (jsmol)interactive image smiles cc1ccc(f)c(nc(=o)nc2ccc(-c3cccc4nc(n)c34)cc2)c1 inchi inchi=1s/c21h18fn5o/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11h,1h3,(h3,23,26,27)(h2,24,25,28)key:mpvgzugxcqextm-uhfffaoysa-n (verify)